#1 Clinical Trials Search in Europe

Ads-010

A new drug called ADS-010, also known as ARO-DUX4, is being studied in clinical trials for the treatment of Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1). This article will provide information about the ongoing research, including the purpose of the study, who can participate, and what the trial involves.

Table of Contents

What is ADS-010?

ADS-010, also known as ARO-DUX4, is an investigational drug being developed to treat Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1). It is a solution for injection that is administered intravenously (through a vein)[1]. The drug is classified as a nucleic acid-based medication, which means it works at the genetic level to potentially address the underlying cause of FSHD1[1].

FSHD1: An Overview

Facioscapulohumeral Muscular Dystrophy (FSHD) is a genetic disorder that causes progressive muscle weakness. It typically affects the muscles of the face (facio-), shoulder blades (scapulo-), and upper arms (humeral)[1]. Type 1 FSHD, which ADS-010 aims to treat, is the most common form of this condition.

Clinical Trial Details

A clinical trial is currently underway to evaluate ADS-010. This study is a Phase 1/2a trial, which means it’s an early-stage study focusing on the drug’s safety, how it’s processed by the body, and its initial effectiveness[1]. Here are some key details about the trial:

  • The trial is titled “A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DUX4 in Adult Patients with Facioscapulohumeral Muscular Dystrophy Type 1”[1].
  • It’s designed to test different doses of ADS-010, both as single doses and multiple doses over time[1].
  • The study is divided into two parts: Part 1 lasts for 90 days, while Part 2 extends to 360 days[1].

Eligibility Criteria

To participate in this study, patients must meet certain criteria. Some of the key eligibility requirements include:

  • Genetically confirmed FSHD1[1].
  • A Clinical Severity Score (CSS) between 3 and 8 on a scale of 0 to 10. This score helps measure the severity of the disease[1].
  • Age 18 or older, with an upper limit of 70 years[1].
  • Ability to undergo a muscle biopsy and MRI[1].

There are also several conditions that would exclude a person from participating, such as certain medical histories, use of specific medications, or inability to comply with study requirements[1].

Study Objectives

The main goals of this clinical trial are:

  1. To assess the safety and tolerability of ADS-010 in patients with FSHD1. This involves monitoring any side effects or adverse reactions that occur during the study[1].
  2. To study the pharmacokinetics (PK) of ADS-010. This refers to how the drug moves through the body, including how it’s absorbed, distributed, metabolized, and excreted[1].
  3. To examine the pharmacodynamics (PD) of ADS-010. This involves studying how the drug affects the body and whether it produces the desired therapeutic effect[1].

Potential Benefits and Risks

As ADS-010 is still in the early stages of testing, its benefits and risks are not yet fully known. The potential benefits could include improved muscle function or slowed disease progression in FSHD1 patients. However, as with any experimental treatment, there may be risks or side effects that have not yet been identified[1].

It’s important to note that participation in clinical trials is voluntary, and patients should discuss the potential risks and benefits with their healthcare providers before deciding to participate[1].

Aspect Details
Drug Name ADS-010 (ARO-DUX4)
Condition Studied Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1)
Study Type Phase 1/2a Dose-Escalating Study
Main Objective Evaluate safety, tolerability, pharmacokinetics, and pharmacodynamics of ADS-010
Participant Age Range 18 to 70 years old
Key Inclusion Criteria Genetically confirmed FSHD1, Clinical Severity Score 3-8, eligible lower extremity muscle for biopsy
Key Exclusion Criteria Recent participation in other studies, certain medical conditions, use of specific medications
Administration Method Intravenous infusion
Study Duration Part 1: 90 days, Part 2: 360 days

FAQ

  • What is ADS-010 and what is it being studied for? ADS-010, also known as ARO-DUX4, is a new drug being studied for the treatment of Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1). The clinical trial aims to evaluate its safety, how well it's tolerated, how it moves through the body, and its effects on the disease.
  • Who can participate in this clinical trial? The trial is open to adults aged 18 to 70 with genetically confirmed FSHD1. Participants must have a clinical severity score between 3 and 8, and meet other specific health criteria. Both men and women can participate, but women must not be pregnant or breastfeeding.
  • What does the clinical trial involve? The trial involves taking the drug ADS-010 through intravenous infusion. Participants will undergo various assessments, including blood tests, muscle biopsies, and MRI scans. The study will monitor for any side effects and measure how the drug affects the body.
  • How long does the clinical trial last? The trial has two parts. Part 1 lasts for 90 days, while Part 2 extends to 360 days. The exact duration for each participant may vary depending on which part of the study they are in.
  • Are there any risks involved in participating? As with all clinical trials, there may be risks involved. The study is designed to evaluate the safety of ADS-010, so participants will be closely monitored for any adverse effects. Specific risks will be explained in detail to potential participants before they agree to join the study.

Ongoing Clinical Trials on Ads-010

  • Study of ADS-010 for Adults with Facioscapulohumeral Muscular Dystrophy Type 1

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Italy The Netherlands Spain

Glossary

  • Facioscapulohumeral Muscular Dystrophy Type 1 (FSHD1): A genetic disorder causing muscle weakness and loss, primarily affecting the face, shoulder blades, and upper arms.
  • Clinical Severity Score (CSS): A scale from 0 to 10 used to measure the severity of FSHD1 symptoms in patients.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.
  • MRI: Magnetic Resonance Imaging, a non-invasive imaging technique used to examine organs and tissues in the body.
  • Muscle Biopsy: A medical procedure where a small sample of muscle tissue is removed for examination.
  • Intravenous Infusion: A method of delivering medications directly into a vein using a needle or catheter.
  • Treatment-Emergent Adverse Events (TEAEs): Any unfavorable medical occurrence that appears or worsens after starting a medical treatment.
  • Glomerular Filtration Rate (GFR): A measure of how well the kidneys are filtering waste from the blood.
  • ALT and AST: Liver enzymes (Alanine Transaminase and Aspartate Transaminase) used to assess liver function.

References

  1. http://clinicaltrials.eu/trial/study-of-ads-010-for-adults-with-facioscapulohumeral-muscular-dystrophy-type-1/